Patent Litigation – Multibagger Upside
1 Main Capital Partners has recently highlighted an interesting legal special situation with ParkerVision (PRKR). You can find the full letter here. PRKR also has a brief 7-minute video explaining the background of the case.
ParkerVision has been locked in a long legal battle with Qualcomm (QCOM) over alleged infringement of its proprietary breakthrough radiofrequency technology, widely used in devices like smartphones. Back in the early 2000s, QCOM was negotiating the licensing this technology. Internal emails uncovered during discovery are showing substantial interest with Qualcomm’s executives and engineers describing ParkerVision’s tech as “the holy grail of RF receiver designs” and “critical technology we must land.” Another email also noted, “I think it’s going to be very difficult for anybody to use this technique without stepping on one or more of their (patent) claims”.
Although the initial negotiations fell through, Qualcomm has continued to show interest and request samples. In 2004, QCOM held internal meetings on “adopting ParkerVision’s approach”. Two years later, in 2006, the chip giant began (allegedly) using PRKR’s technology without a license. ParkerVision only became aware of this in 2011 after QCOM published a technical paper detailing the technology’s use and integration. This sparked the current lawsuit.
The litigation has been long and complex, dragging on for over a decade. However, PRKR has recently won a key appeal regarding expert reports. It now seems likely that the case will finally go to trial in H1 2025. Qualcomm appears boxed in by its own previous arguments, neutralized by the recent appeal decision as well smoking gun internal emails. PRKR is seeking $1.3bn in damages based on 1.6 billion infringed units. With pre-judgment interest, the damages could double to $2.6bn. These multi-billion dollar figures compare to $80m current PRKR capitalization. After fees and taxes, proceeds could amount to $8.2/share, about 8.5x the current stock price. Upside would be even higher if willful infringement is found. PRKR also has lawsuits against other major players like Apple, LG, and NXP.
However, if the legal battle fails, the downside would probably be 100%. While the optical risk-reward might look compelling, legal special situations are notoriously challenging, and even experts who specialize in them often get it wrong. Almost all similar cases previously highlighted on SSI have more or less failed, except for the recent FNCH win. The risks here are considerable, and sizing positions carefully is essential. This is not investment advice; conduct your own due diligence before investing.
Note: The ‘Ideas Elsewhere’ section is intended to highlight interesting event-driven investment ideas by other authors. These ideas are not my own, and I am simply summarizing them to bring the attention of SSI subscribers. I might not actively follow the developments of these ideas, so there might be limited updates or follow-ups in the comments section.
Guys, can anyone recommend a good website where I can follow the progress of court cases in the USA?
Try using Pacer. Some sources that might also be helpful:
– Justia
– CourtListener
– CaseText
– Law360
– State Court Websites
– SCOTUSblog
Anyone keeping up with this that can explain if the recent pull back is based on anything significant?
Or even translate the latest legal update?
ParkerVision Files Reply in U.S. Supreme Court Cert. Petition Calling for End to Federal Circuit’s Use of Rule 36 in PTAB Appeals
I asked Grok about Parker’s comments on the supreme court decision denying the cert position and here’s what I got after feeding it the original writeup and most recent PR. Anyone have more knowledgeable feedback?
Conclusion: Does This Tie to Qualcomm?
Based on the available data:
Unlikely Direct Tie: The ‘940 patent, central to the Qualcomm case, has its method claims intact and trial-ready post-CAFC September 2024. The cert petition likely challenged the Rule 36 affirmance of the ‘940 patent’s apparatus claim invalidation or a separate patent’s full invalidation. Since PRKR-2 relies on the ‘940 patent’s method claims (supported by intrinsic evidence like Figure 64A and Qualcomm’s own admissions), the Supreme Court denial doesn’t appear to undermine the Qualcomm trial directly.
Possible Indirect Effect: If the ‘940 apparatus claims are involved, Qualcomm could argue at trial that the patent’s scope is narrowed, though this seems secondary given the method claims’ strength. More likely, the cert petition addressed a different patent (e.g., from PRKR-1 or another dispute), making it a systemic issue for PRKR’s portfolio rather than a Qualcomm-specific blow.
Parker’s Perspective: His disappointment reflects a lost chance to reform Rule 36, which PRKR sees as a barrier to fair patent defense. The amicus support underscores this as a broader IP fight, not necessarily a Qualcomm-centric one.
Without the exact PTAB case number or patent tied to the cert petition, I can’t confirm with certainty. However, given the ‘940 patent’s method claims driving PRKR-2 and their upheld status, the Supreme Court denial most likely doesn’t tie directly to the Qualcomm trial’s core patents. It’s a setback for PRKR’s wider IP strategy, but the Qualcomm case—projected for mid-2025—remains on track per Parker’s earnings optimism about the CAFC remand and upcoming trial scheduling.
Explain Rule 36 further
Other patent litigation strategies
TLDR – the Supreme Court denial most likely doesn’t tie directly to the Qualcomm trial’s core patents. It’s a setback for PRKR’s wider IP strategy, but the Qualcomm case—projected for mid-2025—remains on track per Parker’s earnings optimism about the CAFC remand and upcoming trial scheduling
Looks like another court/timing setback – anyone knowledgeable have comments?